Partner with compliance, commercial and medical affairs executives in the life sciences (pharmaceuticals, biotechnology, medical devices / medical technology) to develop solutions to ensure compliance with the US Physician Payment Sunshine Act, anti-kickback and anti-bribery statutes, and worldwide transparency and disclosure legislation. Specialize in fair-market value (FMV) rate assessments and policies and procedures governing fair-market value compensation of healthcare providers (HCPs)… Show more Partner with compliance, commercial and medical affairs executives in the life sciences (pharmaceuticals, biotechnology, medical devices / medical technology) to develop solutions to ensure compliance with the US Physician Payment Sunshine Act, anti-kickback and anti-bribery statutes, and worldwide transparency and disclosure legislation. Specialize in fair-market value (FMV) rate assessments and policies and procedures governing fair-market value compensation of healthcare providers (HCPs), thought leaders, key opinion leaders (KOLs), specialists and non-providers (payers, advocacy group board members, hospital executives, etc.). Advise clients on HCP compensation policies and procedures to establish compliance with government anti-kickback legislation and local market compensation cap rates around the globe.Selected areas of responsibility and expertise include:- managing client relationships for several top-20 companies with global HCP compensation programs and dozens of mid-sized and small pharmaceutical, biotech and medical technology firms with international, regional and country-level programs- advising clients on compliance with The Physician Payment Sunshine Act and transparency and disclosure requirements worldwide- travel and hospitality compensation policies, procedures, calculations and trends analysisCutting Edge Information is the market leader in providing FMV rates and related analysis to the life sciences. We provide FMV rates for more than 175 life sciences companies, including 7 of the top 10 pharmaceutical companies and more than half of the pharmaceutical industry's top 50 firms. We also serve a diverse client base in medical technology, as more than 20% of our clients are medical device / medtech firms. Show less

Energy Decisions Group is a global business intelligence and decision support firm serving the energy sector. We provide senior executives with primary business research -- data, executive insights, and innovative business practices -- to inform critical strategic and operational decision making. Our focus spans oil and gas (including fuel extraction, refining, manufacturing and distribution) and utilities (including electric, coal, nuclear and renewables). We provide business intelligence… Show more Energy Decisions Group is a global business intelligence and decision support firm serving the energy sector. We provide senior executives with primary business research -- data, executive insights, and innovative business practices -- to inform critical strategic and operational decision making. Our focus spans oil and gas (including fuel extraction, refining, manufacturing and distribution) and utilities (including electric, coal, nuclear and renewables). We provide business intelligence, market insights and decision support services through two core channels: 1.) primary business intelligence reports, and 2.) customized research and decision support services. Show less

Worked closely with senior executives at many top global pharmaceutical and biotechnology companies to build and maintain new and existing client relationships supporting commercial insights and market analytics needs at key accounts. Served as the primary point of contact with clients in the C-suite (CEO, chief compliance officer, chief medical officer, chief commercial officer), vice presidents, directors and managers, and was responsible for:1. Interfacing directly with key… Show more Worked closely with senior executives at many top global pharmaceutical and biotechnology companies to build and maintain new and existing client relationships supporting commercial insights and market analytics needs at key accounts. Served as the primary point of contact with clients in the C-suite (CEO, chief compliance officer, chief medical officer, chief commercial officer), vice presidents, directors and managers, and was responsible for:1. Interfacing directly with key stakeholders at more than one-third of the top 50 global pharmaceutical and biotech companies; dozens of small and mid-sized specialty drug companies; numerous global professional services and consulting firms; and other industry service providers.2. Collaborating with industry executives in various compliance, commercial, medical and clinical roles to: a. identify unmet commercial analytics, market insights, business intelligence, operational, strategic and decision support needs b. understand clients' pain points, key objectives, budgets, and timelines c. partner with members of Cutting Edge Information's executive leadership, research and consulting teams to develop strategies and conceptualize solutions to best meet clients' needs d. communicate solutions and build buy-in with individual client decision makers and among members of client decision-making teams (often balancing differing and, sometimes, contradictory objectives) e. write proposals to win new business f. leverage my unique background as an industry analyst, market researcher and consultant to partner with our project teams to deliver top-notch market analysis, insights, data and client deliverables g. manage projects and client relationships from inception through implementation. Show less

Collaborated with Cutting Edge Information's CEO, COO, and heads of sales, marketing, research and consulting teams to develop strategies and oversee execution of projects leveraging the company's existing knowledge assets to better serve client needs and drive substantial revenue increases. These assets included our company's institutional knowledge developed through prior years' work, including pharma and biotech market intelligence databases, quantitative and qualitative market analytics… Show more Collaborated with Cutting Edge Information's CEO, COO, and heads of sales, marketing, research and consulting teams to develop strategies and oversee execution of projects leveraging the company's existing knowledge assets to better serve client needs and drive substantial revenue increases. These assets included our company's institutional knowledge developed through prior years' work, including pharma and biotech market intelligence databases, quantitative and qualitative market analytics reports, and executive presentation slide decks spanning numerous functions and topics, including:MARKET ACCESS:- federal, state, and trade payer relationship management- regional and national field-based account management- health economics and health outcomes research- health outcomes and managed care liaison teams- pricing strategy and analysis- product reimbursement strategyNEW PRODUCT MARKETING AND BRAND MANAGEMENT:- early-stage market preparation / pre-launch commercialization planning and operations- launch-phase commercialization strategy, operations, resource allocation and performance measurement and improvement- in-line brand lifecycle management strategy- late-stage lifecycle management, including counter-generics strategyFIELD SALES OPERATIONS- sales force sizing and alignment (sales rep/DM/RM staffing and alignment, experience setting up mirrored sales forces)- specialty and hospital sales force management- operational performance improvement and tracking (office calls, e-detailing, sample strategies, and operating expense management)MEDICAL AFFAIRS- field-based MSL team operations, staffing, organizational structure, compensation, and key performance metrics in the US, Europe, Asia-Pacific and select emerging markets- medical publications- investigator-initiated studies management- advisory boards- medical information.... and various topics in market research, competitive intelligence, business development and clinical development. Show less

Performed tax compliance analysis and tax filing preparation for numerous corporate clients, including pharmaceutical and biotechnology companies and other clients of the firm's Technology & Life Sciences practice.

Gained progressive experience leading project teams consisting of 3-5 team members. Developed both syndicated and customized/client-driven market analysis and market research projects for global pharmaceutical and biotechnology clients. Clients included nearly all of the top 50 pharmaceutical/biotech companies and numerous small and mid-sized companies. Project deliverables consisted of written reports, executive presentation slide decks, PowerPoint slide modules, and Excel databases. Honed… Show more Gained progressive experience leading project teams consisting of 3-5 team members. Developed both syndicated and customized/client-driven market analysis and market research projects for global pharmaceutical and biotechnology clients. Clients included nearly all of the top 50 pharmaceutical/biotech companies and numerous small and mid-sized companies. Project deliverables consisted of written reports, executive presentation slide decks, PowerPoint slide modules, and Excel databases. Honed quantitative analysis skills while refining ability to inject qualitative insights and other "soft" commercial and market sign-posts to deliver more meaningful insights and valuable analysis for clients. Leveraged primary and secondary data sources to identify business opportunities and unmet needs and to refine project findings and polish client deliverables.Author of numerous articles on market analysis and commercial insights published in trade journals and industry publications, including Pharmaceutical Executive, PharmaVoice, and Journal of Generic Medicines.Led projects and served as the primary author and creator of client deliverables for the following syndicated business intelligence projects:1. Pharmaceutical Pricing in the US and Europe (2005)2. Managed Markets: Pharmaceutical Reimbursement Strategy, Organizational Structure and Medicare Part D (2006)3. Investigator-Initiated Clinical Trials: Structure, Process and Strategy (2006)4. Small and Specialty Drug Branding: Tapping Niche Market Potential (2006)5. Marketing Mid-Tier Pharmaceutical Brands: Winning Resources for Near-Blockbusters (2006)6. Blockbuster Pharmaceutical Launches: Establishing Market Leadership (2006)7. Post-Launch US Marketing: Promotional Mix, Decision Support and Market Access (2006)8. Clinical Operations: Accelerating Trials, Allocating Resources and Measuring Performance (2006)9. Phase 4 Clinical Trials: Post-Marketing Study Management Structure, Strategy and Benchmarks (2007) Show less

Led project teams to develop syndicated and customized/client-driven market analysis and market research projects for clients at virtually all of the top 50 global pharma/biotech companies. Developed and refined a skill set anchored in quantitative methods and data analytics, balanced with pertinent qualitative insights to properly position findings and recommendations for clients.Developed a client relationship, sold the project, and served as project lead on a year-long… Show more Led project teams to develop syndicated and customized/client-driven market analysis and market research projects for clients at virtually all of the top 50 global pharma/biotech companies. Developed and refined a skill set anchored in quantitative methods and data analytics, balanced with pertinent qualitative insights to properly position findings and recommendations for clients.Developed a client relationship, sold the project, and served as project lead on a year-long multi-national engagement for UCB Pharma (formerly Schwarz Biosciences) to establish a new Clinical Trial Operations function matrixed across all business units/development programs. Project had significant exposure to the Chief Medical Officer. Worked closely with more than 50 clinical and supporting executives in the US and Germany to identify operating needs, set priorities and establish a strategy and mandate for this new department.Primary author and creator of client deliverables for the following syndicated commercial insights and market analysis projects:1. Combating Generics: Pharmaceutical Brand Defense (2004)2. Accelerating Clinical Trials: Budgets, Patient Recruitment and Productivity (2004)3. Early-Stage Pharmaceutical Marketing: Global Budgets and Staffing, Pre-Clinical to Phase 3 (2005)4. Pharmaceutical Sales: Driving Access and Influencing Prescribers (2005)5. European Pharmaceutical Marketing: Launching Successful Brands (2005)6. Pharmaceutical Medical Publications: Winning Physician Support (2005)Secondary author and creator of deliverables for six additional syndicated commercial insights and market analysis projects focused on alliances and licensing, patient compliance and disease management, cardiovascular product commercialization, market research and competitive intelligence departments, and global product launches. Show less

I worked as an analyst and, ultimately, as a project team leader on numerous consulting engagements delivering market insights, commercial analytics and business intelligence projects for many of the world's top pharmaceutical and biotechnology companies, including Eli Lilly, GlaxoSmithKline (formerly GlaxoWellcome), Sanofi (formerly Aventis), Novartis, Roche, Merck, AstraZeneca, and Abbott Laboratories.Select project contributions included:- Eli Lilly: Served as primary point… Show more I worked as an analyst and, ultimately, as a project team leader on numerous consulting engagements delivering market insights, commercial analytics and business intelligence projects for many of the world's top pharmaceutical and biotechnology companies, including Eli Lilly, GlaxoSmithKline (formerly GlaxoWellcome), Sanofi (formerly Aventis), Novartis, Roche, Merck, AstraZeneca, and Abbott Laboratories.Select project contributions included:- Eli Lilly: Served as primary point of contact and led project engagement to assess and determine best practices in manufacturing quality control laboratories. (2002)- Eli Lilly: Supported implementation of a new, mirrored sales force structure in the US market. Project had visibility to the CEO and President of US Pharmaceuticals. (2000-2002)- GlaxoSmithKline: Developed operating strategy and market analysis to support priority setting for the US head of predictive medicine. Gained exposure to numerous advisory board meetings. (2001-2002)- GlaxoSmithKline: Analyzed US field sales organization's effectiveness and physician perception of GSK's field sales representatives through interviews and consultations with primary care and specialty physicians across the US. (2001)- GlaxoSmithKline: Supported a new product/diagnostic (Rx/Dx) co-development and launch by providing market insights, identifying best practices, and analyzing key operational and performance benchmarks. (2001-2002)- Roche: Established new product commercialization budget, staffing and timeline benchmarks to support client's US new product commercialization team. (2000-2001) Show less